InsiderSignal.AI

InsiderSignal.ai

NUVL - Nuvalent, Inc.

Insider Sale by Porter James Richard (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Porter James Richard, serving as Pres, CEO at Nuvalent, Inc. (NUVL), sold 30,000 shares at $103.77 per share, for a total transaction value of $3,113,231.00. Following this transaction, Porter James Richard now holds 324,879 shares of NUVL.

This sale represents a 8.00% decrease in Porter James Richard's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, April 6, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 8, 2026, 2 days after the trade was made.

Nuvalent, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Porter James Richard

Pres, CEO

James R. Porter, Ph.D. (age 49) is the President, Chief Executive Officer, and Director of Nuvalent, Inc. (NASDAQ: NUVL), positions he has held since February 2020.[[1]](https://fintool.com/app/research/companies/NUVL/people/james-porter)[[3]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nuvl/nuvalent/management) He joined Nuvalent in early 2018 as a consultant and later served as Vice President of Product Development from April 2018 to January 2020, leading product development efforts during the company's formation.[[1]](https://fintool.com/app/research/companies/NUVL/people/james-porter)[[4]](https://www.insidertrades.com/nuvalent-inc-stock/james-richard-porter/) Porter owns approximately 249,062 to 324,879 shares of Nuvalent stock, valued at $19–34 million as of early 2026, reflecting his significant insider stake.[[2]](https://www.gurufocus.com/insider/185827/james-richard-porter)[[4]](https://www.insidertrades.com/nuvalent-inc-stock/james-richard-porter/) Porter brings over two decades of experience in oncology drug development.[[4]](https://www.insidertrades.com/nuvalent-inc-stock/james-richard-porter/)[[6]](https://www.sec.gov/Archives/edgar/data/1861560/000119312521209001/d174530ds1.htm) He spent 15 years at Infinity Pharmaceuticals (2002–2016), rising to Vice President of Product Development, where he led teams through the NDA submission and FDA approval of COPIKTRA (duvelisib) and contributed to six compounds entering clinical trials.[[1]](https://fintool.com/app/research/companies/NUVL/people/james-porter) In 2017, he consulted for Verastem Oncology, overseeing the NDA submission for duvelisib post-acquisition.[[1]](https://fintool.com/app/research/companies/NUVL/people/james-porter) He holds a B.A. in chemistry from the College of the Holy Cross and a Ph.D. in organic chemistry from Boston College.[[1]](https://fintool.com/app/research/companies/NUVL/people/james-porter) Under his leadership, Nuvalent has advanced its pipeline, including completing the rolling NDA for zidesamtinib, with a cash runway into 2028.[[1]](https://fintool.com/app/research/companies/NUVL/people/james-porter)

View full insider profile →

Trade Price

$103.77

Quantity

30,000

Total Value

$3,113,231.00

Shares Owned

324,879

Trade Date

Monday, April 6, 2026

3 days ago

SEC Filing Date

Wednesday, April 8, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Nuvalent, Inc.

Company Overview

No company information available
View news mentioning NUVL

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5473358

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime